Liang Xu, Ph.D. member of the KU Cancer Center's Drug Discovery, Delivery and Experimental Therapeutics program and associate professor of molecular biosciences at KU, has discovered that targeting a cell - surface receptor called «CD44s» can
block pancreatic tumor formation and recurrence after radiotherapy.
Not exact matches
With this information, the scientists tested the glucose -
blocking anti-diabetes drug metformin, combined with the nanoparticle - encapsulated BPTES, on another eight mice implanted with human
pancreatic tumors.
The researchers demonstrated that
blocking the PGD enzyme genetically or with a pharmacologic inhibitor reversed the epigenetic reprogramming and malignant gene expression changes detected in distant metastases, and also strongly inhibited their
tumor - forming capacity, with no effect on normal cells or peritoneal
pancreatic cancer controls.
To validate their findings, the scientists injected the novel nanoparticles into
pancreatic tumor - bearing mice and observed that by balancing these two targets — bringing them to a normal level by increasing their expression or
blocking the gene responsible for their expression — they significantly prolonged the survival of the mice.
«Potential
pancreatic cancer target challenged: New research finds PDX1 critical for cancer growth, but
blocking it may lead to more aggressive
tumors.»
People with
pancreatic cancer may also itch — not from the cancer itself, but from a
tumor blocking the bile duct.